#SARS-CoV-2

While regular boosters may help keep vulnerable people out of the hospital, annual boosters might not be necessary for everyone.

Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.

Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.

The antiviral treatment reduced the risk of hospitalization or death from SARS-CoV-2 Omicron variants in older adults by 44%.

As new cases of acute hepatitis among kids have declined, questions remain unanswered.

Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.

Fauci, who has directed the National Institute of Allergy and Infectious Diseases since 1984, will step down in December.

COVID-19 test results provide valuable data that public health departments can use to assess needs and modify responses.

These three respiratory illnesses—and others—share many of the same symptoms.

Updated boosters could go to the “worried well” who have good insurance rather than to those at highest risk.

Whether omicron coronavirus variants cause long COVID symptoms as often—and as severe—as previous variants is a matter of heated study.

The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.

The update aims to help the public better protect themselves and understand their risk.

New studies offer evidence that an unexpected virus plays a role—but it needs a helper.

Antibody levels decrease substantially within three months after a booster, according to new clinical trial data.

Two drugs widely used to treat certain autoimmune diseases substantially improved clinical status and reduced deaths.